The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss
 
Daniel Wilhelm Mueller
No Relationships to Disclose
 
Mohammad-Reza Rafiyan
No Relationships to Disclose
 
Dragan Kiselicki
No Relationships to Disclose
 
Timursah Habibzade
No Relationships to Disclose
 
Marina Schaaf
No Relationships to Disclose
 
Regina Eickhoff
No Relationships to Disclose
 
Elke Jäger
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Immutep; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma